JP2010533498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533498A5 JP2010533498A5 JP2010517161A JP2010517161A JP2010533498A5 JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5 JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 4
- 102000048373 human GPC3 Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000010956 Glypican Human genes 0.000 claims 2
- 108050001154 Glypican Proteins 0.000 claims 2
- 108050007237 Glypican-3 Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95984507P | 2007-07-17 | 2007-07-17 | |
| US60/959,845 | 2007-07-17 | ||
| PCT/US2008/070344 WO2009012394A1 (en) | 2007-07-17 | 2008-07-17 | Monoclonal antibodies against glypican-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014137921A Division JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010533498A JP2010533498A (ja) | 2010-10-28 |
| JP2010533498A5 true JP2010533498A5 (enExample) | 2011-07-21 |
| JP5868593B2 JP5868593B2 (ja) | 2016-02-24 |
Family
ID=39874207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517161A Expired - Fee Related JP5868593B2 (ja) | 2007-07-17 | 2008-07-17 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| JP2014137921A Pending JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014137921A Pending JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8680247B2 (enExample) |
| EP (1) | EP2178921B1 (enExample) |
| JP (2) | JP5868593B2 (enExample) |
| KR (2) | KR101527342B1 (enExample) |
| CN (1) | CN101815726B (enExample) |
| AU (1) | AU2008275985B2 (enExample) |
| CY (1) | CY1117236T1 (enExample) |
| DK (1) | DK2178921T3 (enExample) |
| ES (1) | ES2562790T3 (enExample) |
| HR (1) | HRP20160270T1 (enExample) |
| HU (1) | HUE028737T2 (enExample) |
| ME (1) | ME02345B (enExample) |
| MX (1) | MX2010000537A (enExample) |
| PL (1) | PL2178921T3 (enExample) |
| PT (1) | PT2178921E (enExample) |
| RS (1) | RS54624B1 (enExample) |
| SI (1) | SI2178921T1 (enExample) |
| WO (1) | WO2009012394A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| IN2014DN10515A (enExample) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| JP5868593B2 (ja) * | 2007-07-17 | 2016-02-24 | メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| AR066172A1 (es) * | 2007-09-28 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica. |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| CN102875677A (zh) * | 2009-05-08 | 2013-01-16 | 霍夫曼-拉罗奇有限公司 | 人源化抗egfl7抗体及其使用方法 |
| EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| MX345399B (es) * | 2010-12-28 | 2017-01-30 | Chugai Pharmaceutical Co Ltd | Metodo de cultivo de celulas animales. |
| CN103596985B (zh) | 2011-04-19 | 2016-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US20140322216A1 (en) * | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| SI2956173T1 (sl) | 2013-02-14 | 2017-06-30 | Bristol-Myers Squibb Company | Spojine tubulizina, postopki pridobivanja in uporaba |
| MX368016B (es) | 2013-08-14 | 2019-09-13 | Univ Rice William M | Derivados de uncialamicina, métodos de sintesis y su uso como agentes antitumor. |
| SG10201803449VA (en) | 2013-09-27 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| LT3221346T (lt) | 2014-11-21 | 2020-11-10 | Bristol-Myers Squibb Company | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis |
| CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
| ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
| WO2016115191A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN105037540A (zh) * | 2015-05-13 | 2015-11-11 | 北京比洋生物技术有限公司 | 抗磷脂酰肌醇蛋白聚糖3全人源抗体 |
| AU2016262845B2 (en) | 2015-05-18 | 2020-07-23 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| US10273275B2 (en) | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| JP6762485B2 (ja) * | 2015-06-24 | 2020-09-30 | 学校法人慶應義塾 | 抗グリピカン−１−免疫抗原受容体 |
| KR102777002B1 (ko) * | 2015-08-03 | 2025-03-05 | 크라제 메디컬 씨오 리미티드 | 항글리피칸-3 항체 및 이의 응용 |
| KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
| JP2019505575A (ja) | 2015-12-21 | 2019-02-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 部位特異的な結合のための変異型抗体 |
| CN105717303A (zh) * | 2016-01-29 | 2016-06-29 | 山东康力医疗器械科技有限公司 | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 |
| TW202214700A (zh) | 2016-03-14 | 2022-04-16 | 日商中外製藥股份有限公司 | 用於癌之治療的細胞傷害誘導治療劑 |
| US20170326249A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| CN106084041A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 一种全人源抗GPC3的全分子IgG抗体及其应用 |
| EP3490589A1 (en) | 2016-07-26 | 2019-06-05 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| ES2902179T3 (es) | 2016-08-19 | 2022-03-25 | Bristol Myers Squibb Co | Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso |
| WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
| MX420947B (es) | 2017-04-26 | 2025-02-10 | Eureka Therapeutics Inc | Constructos que reconocen específicamente glipicano 3 y usos de estos. |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| CN109988240B (zh) * | 2017-12-29 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗gpc-3抗体及其用途 |
| AU2019277094B2 (en) | 2018-05-29 | 2025-12-18 | Bristol-Myers Squibb Company | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| BR112021010060B1 (pt) | 2018-11-30 | 2024-03-12 | Bristol-Myers Squibb Company | Anticorpo que compreende uma extensão c-terminal de cadeia leve que contém glutamina, conjugados do mesmo, e método de preparação de conjugados |
| WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| US12404341B2 (en) | 2019-03-21 | 2025-09-02 | Agency For Science, Technology And Research | Glypican-3 (GPC-3) antibodies |
| CN112390886B (zh) * | 2019-08-16 | 2022-08-16 | 原启生物科技(上海)有限责任公司 | 一种分离的抗原结合蛋白及其用途 |
| WO2021216916A1 (en) | 2020-04-22 | 2021-10-28 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins |
| BR112022020716A2 (pt) * | 2020-05-07 | 2022-11-29 | Phanes Therapeutics Inc | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |
| EP4262985A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| JP2024515201A (ja) * | 2021-04-23 | 2024-04-05 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｇｐｃ３抗体及び使用方法 |
| CN113354737B (zh) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 |
| MX2024002121A (es) * | 2021-08-19 | 2024-07-10 | Adicet Therapeutics Inc | Métodos para la detección del glipicano-3 unido a la membrana. |
| WO2023061505A1 (en) * | 2021-10-15 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Anti-glypican 3 antibodies |
| CN120344270A (zh) | 2022-10-07 | 2025-07-18 | Ambrx 公司 | 药物接头及其抗体缀合物 |
| WO2024094017A1 (zh) * | 2022-11-01 | 2024-05-10 | 上海齐鲁制药研究中心有限公司 | 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用 |
| AU2024305352A1 (en) | 2023-06-12 | 2025-12-04 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3426001B2 (ja) | 1993-09-16 | 2003-07-14 | 東芝機械株式会社 | ステージ内蔵型雰囲気室装置 |
| EP0822830B1 (en) * | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| ES2312586T3 (es) | 2001-06-22 | 2009-03-01 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor del crecimiento celular que contenga un anticuerpo anti-clipicano 3. |
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| WO2004022595A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | MRL/lprマウスを用いた抗体の作製 |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| US7303914B2 (en) | 2003-01-30 | 2007-12-04 | Hongyang Wang | Monoclonal antibody against human hepatoma and use thereof |
| CN101562197B (zh) | 2003-06-27 | 2011-08-10 | 日本电气株式会社 | 薄膜晶体管、薄膜晶体管基板及电子设备 |
| PL1674111T3 (pl) | 2004-07-09 | 2011-04-29 | Chugai Pharmaceutical Co Ltd | Przeciwciała anty-glipikan 3 |
| KR20130103580A (ko) | 2004-08-24 | 2013-09-23 | 추가이 세이야쿠 가부시키가이샤 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
| JP4794457B2 (ja) | 2004-10-26 | 2011-10-19 | 中外製薬株式会社 | 糖鎖改変抗グリピカン３抗体 |
| DE602005027258D1 (de) * | 2005-03-14 | 2011-05-12 | Us Gov Health & Human Serv | Humane monoklonale antikörper gegen hendra- und nipah-viren |
| EA019344B1 (ru) * | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US7744800B2 (en) | 2006-01-06 | 2010-06-29 | Molded Fiber Glass Companies | Method and apparatus for controlling the stacking height of stackable products during compression molding off stops |
| BRPI0717902A2 (pt) * | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
| JP5868593B2 (ja) * | 2007-07-17 | 2016-02-24 | メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
-
2008
- 2008-07-17 JP JP2010517161A patent/JP5868593B2/ja not_active Expired - Fee Related
- 2008-07-17 MX MX2010000537A patent/MX2010000537A/es active IP Right Grant
- 2008-07-17 PT PT87962494T patent/PT2178921E/pt unknown
- 2008-07-17 PL PL08796249T patent/PL2178921T3/pl unknown
- 2008-07-17 ES ES08796249.4T patent/ES2562790T3/es active Active
- 2008-07-17 DK DK08796249.4T patent/DK2178921T3/en active
- 2008-07-17 AU AU2008275985A patent/AU2008275985B2/en not_active Ceased
- 2008-07-17 KR KR1020157007446A patent/KR101527342B1/ko not_active Expired - Fee Related
- 2008-07-17 KR KR1020107003345A patent/KR101570252B1/ko not_active Expired - Fee Related
- 2008-07-17 CN CN2008801031669A patent/CN101815726B/zh not_active Expired - Fee Related
- 2008-07-17 SI SI200831584A patent/SI2178921T1/sl unknown
- 2008-07-17 ME MEP-2016-86A patent/ME02345B/me unknown
- 2008-07-17 WO PCT/US2008/070344 patent/WO2009012394A1/en not_active Ceased
- 2008-07-17 RS RS20160157A patent/RS54624B1/sr unknown
- 2008-07-17 HR HRP20160270TT patent/HRP20160270T1/hr unknown
- 2008-07-17 EP EP08796249.4A patent/EP2178921B1/en active Active
- 2008-07-17 HU HUE08796249A patent/HUE028737T2/en unknown
- 2008-07-17 US US12/668,965 patent/US8680247B2/en active Active
-
2014
- 2014-02-10 US US14/176,790 patent/US9217033B2/en active Active
- 2014-07-03 JP JP2014137921A patent/JP2014236734A/ja active Pending
-
2016
- 2016-03-01 CY CY20161100174T patent/CY1117236T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533498A5 (enExample) | ||
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| JP2014518615A5 (enExample) | ||
| JP2012523848A5 (enExample) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| HRP20191483T1 (hr) | Protutijela koja reagiraju s b7-h3, njihovi imunološki aktivni fragmenti i njihova upotreba | |
| JP2013545455A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2010511388A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2011526480A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2018502060A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2013545738A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2010526028A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| RU2010136940A (ru) | Антитела против альфа5-бета1 и их применение | |
| JP2013544756A5 (enExample) |